OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Zeidan on Classification and Treatment Updates in MDS

December 1st 2023

Amer Zeidan, MBBS, discusses classification and treatment updates for patients with myelodysplastic syndrome.

Dr Jonasch on the Evolution of Belzutifan in Cancer Care

December 1st 2023

Eric Jonasch, MD, discusses the evolution of belzutifan in cancer care, highlighting the agent’s potential for the treatment of patients with renal cell carcinoma.

Dr Vaishampayan on the Rationale For the SWOG-1931/PROBE Trial in Advanced RCC

December 1st 2023

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.

Dr Mayer on the Use of CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

December 1st 2023

Erica L. Mayer, MD, MPH, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr Gallagher on Unmet Needs With ADCs in Breast Cancer

December 1st 2023

Christopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.

Dr Bazhenova on Perioperative Treatment Selection in EGFR– or ALK-Mutated NSCLC

December 1st 2023

Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.

Dr Levy on the Evolution of ADCs in NSCLC

December 1st 2023

Benjamin Philip Levy, MD, discusses the evolution of antibody-drug conjugates in non-small cell lung cancer following updated data to be read out for this treatment population throughout 2023.

Dr Allan on the Importance of BTK Inhibitors and BCL2 Inhibitors in CLL

December 1st 2023

John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.

Dr Lamanna on the Use of Novel Agents Following Progression in CLL

December 1st 2023

Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.

Dr Kremyanskaya on the Use of Cytoreductive Measures in PV and ET

December 1st 2023

Marina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.

Dr Sparano on Advances in Breast Cancer Screening, Treatment, and Drug Development

December 1st 2023

Joseph A. Sparano, MD, FACP, discusses developments in breast cancer diagnosis and treatment.

Dr Wise on the Importance of Genetic Testing in mCRPC

November 30th 2023

David R. Wise, MD, PhD, discusses the importance of germline and somatic testing in patients with metastatic castration-resistant prostate cancer, and the need for improved testing practices in clinical practice.

Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell Therapy in Solid Tumors

November 30th 2023

Michael Hurwitz, MD, PhD, discusses the ongoing investigation into the use of CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Dr Danish on Post-CAR T-Cell Bridging Radiation Therapy Eligibility in High-Risk NHL

November 29th 2023

Adnan F. Danish, MD, discusses findings from a study evaluating the prevalence of patients with high-risk non-Hodgkin lymphoma who were eligible for bridging radiation therapy prior to receiving CAR T-cell therapy, as well as the outcomes of these patients following CAR T-cell therapy.

Dr Braunstein on the Evolution of ASCT in Multiple Myeloma

November 29th 2023

Marc J. Braunstein, MD, PhD, discusses the evolution of autologous stem cell transplantation and ongoing treatment needed to better determine when ASCT should be recommended for patients with multiple myeloma.

Dr Nathan on the Design of the IMCgp100-202 Trial in Uveal Melanoma

November 29th 2023

Paul D. Nathan, MBBS, PhD, FRCP, discusses the design of the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, highlighting the key enrollment criteria of the randomized, open-label study.

Dr Nathan on the Rationale For Investigating Tebentafusp in Uveal Melanoma

November 29th 2023

Paul D. Nathan, MBBS, PhD, FRCP, discusses the rationale for launching the phase 3 IMCgp100-202 trial evaluating tebentafus in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, as well as the mechanism of action of the agent.

Dr Porter on the Potential Role for Taletrectinib in ROS1+ NSCLC

November 29th 2023

Jason Porter, MD, discusses the potential role of the next-generation TKI taletrectinib in patients with ROS1-positive non–small cell lung cancer, according to data from the phase 2 TRUST-II trial.

Dr Sonpavde on the Efficacy of Frontline Nivolumab Plus Chemotherapy in Metastatic Urothelial Carcinoma

November 29th 2023

Guru P. Sonpavde, MD, discusses the significance of data from the phase 3 CheckMate 901 trial of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma.

Dr Desai on the Implications of the CONTACT-03 Trial in RCC

November 28th 2023

Arpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.